Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

730.65 +15.10 (+2.11%)
Streaming Delayed Price Updated: 12:31 PM EDT, May 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
Via Benzinga
Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals
Real-world studies on GLP-1s like Ozempic show lower weight loss than clinical trials, with high discontinuation rates due to adverse effects, costs, and unmet expectations, raising concerns about... 
Via Benzinga
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
Hims & Hers Health Inc (NYSE:HIMS) shares are trading lower Thursday after the U.S. Food and Drug Administration removed Eli Lilly And Co's (NYSE:LLY) weight-loss and diabetes drugs from its shortage... 
Via Benzinga
This IPO Biotech Stock Could Be the Next Eli Lilly
BioAge has its eyes on a handful of truly gargantuan markets. 
Via The Motley Fool
Topics Initial Public Offering
Exposures Securities Market
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Eli Lilly's Options: A Look at What the Big Money is Thinking
Via Benzinga
Tradepulse Power Inflow Alert: Eli Lilly And Company Climbs 15 Points
Via Benzinga
Is NYSE:LLY a Fit for high Growth Investing Strategies?
Exploring ELI LILLY & CO (NYSE:LLY)'s high growth characteristics. 
Via Chartmill
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
RBC Capital Markets initiates coverage on Tandem Diabetes Care (TNDM) with an Outperform rating and $65 price target, citing growth opportunities in the U.S. Type 1 and Type 2 diabetes markets, product... 
Via Benzinga
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed. 
Via Benzinga
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
Eli Lilly announces a $4.5B investment to build the Lilly Medicine Foundry, a state-of-the-art facility in Indiana. The new center will focus on advanced drug development and manufacturing, reinforcing... 
Via Benzinga
3 Momentum Trades Too Good Pass Up
Check out these three stocks each up over 60% in the past twelve months. Their strong paths for growth can help keep their momentum stories going. 
Via MarketBeat
Topics ETFs
Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation
Eli Lilly is on track to become the first trillion-dollar pharma company, fueled by FDA-approved weight loss drugs. With a current valuation of $842 billion, analysts weigh investor risks as... 
Via Benzinga
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
Via Investor Brand Network
Eli Lilly Eyes New Trials For Weight-Loss Drugs In Non-Obese Patients
Eli Lilly explores expanding its weight-loss drugs, Mounjaro and Zepbound, to individuals with a BMI below 27 to prevent health risks. CEO Dave Ricks emphasizes responsible use amid supply concerns. 
Via Benzinga
Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
Currently, the BMI cut-off for trials is 27 in the U.S. and northern Europe. 
Via Benzinga
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
EQNX::TICKER_START (NYSE:ANVS),(NYSE:LLY),(NYSE:PFE),(NYSE:NVO),(NASDAQ:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC... 
Via Benzinga
Exposures Product Safety
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
Roche focuses on obesity drug development, fast-tracking its CT-388 candidate, and targeting $3.6 billion in annual sales. The company aims to launch 20 transformative drugs by 2030 while cutting... 
Via Benzinga
This Is the Best Pharma Stock to Invest $1,000 in Right Now
Eli Lilly could keep growing for years without changing its strategy. 
Via The Motley Fool
Eli Lilly And Co DCF Valuation: Is The Stock Undervalued?
Based on the DCF valuation, the stock is overvalued. The DCF value of $632.57 share is lower than the current market price of $921.49. The Margin of Safety is -45.67%. 
Via Talk Markets
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
These two players are set on finding the next big therapeutic modality. 
Via The Motley Fool
1 Unstoppable Growth Stock Heading to $2 Trillion by 2030
It's hard to bet against this company right now. 
Via The Motley Fool
Got $1,000? 2 Superior Growth Stocks to Buy and Hold Forever
Eli Lilly and Lululemon operate in very different industries, but both are on promising trajectories. 
Via The Motley Fool
Stocks To Buy And Hold For 5 Years
Growth potential is key for investors who want to buy and hold for 5 years. 
Via Talk Markets
Prediction: Eli Lilly Will Dominate the Billion-Dollar Weight Loss Drug Market for This Key Reason
Eli Lilly is focusing on research and manufacturing. 
Via The Motley Fool
BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO
The company is working on a drug that mimics apelin, which is released following exercise. 
Via Investor's Business Daily
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
The healthcare company's pivot into a new set of technologies will have many implications for the stock. 
Via The Motley Fool
Eli Lilly Stock Soars In 2024 On Weight Loss Drug Success, Now The Company Wants Medical Records Of Copycat Treatments
To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products. 
Via Benzinga
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.